8/19/11 Contest Update
Chalk up one more round for Karl, as out-of-control speculators hammer another nail into capitalism’s coffin. Ok, I admit it. I’ve been spending too much time listening to Dr. Doom.
online.wsj.com
At Friday’s close, the Nasdaq Biotech Index was down -5.20% YTD (vs. down - 2.73% YTD a week ago) and the Contest median was down -9.28% YTD (vs. down -7.85% YTD a week ago). The Nasdaq Composite Index was down -11.72% YTD (vs. down -5.46% YTD a week ago).
Our leader, GENE’s portfolio (up 47.82 % YTD), held up fairly well, with JIBAC’s portfolio (up 28.96%YTD) still in second place and MCBIO’s portfolio (up 26.99% YTD) taking over third place.
At Friday's close, just 10 of the 38 Contest portfolios were in the black, while 14 of the 38 were beating the NBI.
Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks ranked by % Gained and % Lost for the week (foreign stock prices are not converted to US$ in these two tables).
Portfolio adjustments: None
Have a terrific weekend biotechies!
(All corrections, especially adjustments for splits, greatly appreciated.)
8/19/11
Rank Name Profit/Loss
1 GENE 47,818
2 JIBAC 28,955
3 MCBIO 26,993
4 ROCKY 21,312
5 FIB 11,545
6 JULIUS 9,368
7 RKRW 8,265
8 RRGE 4,990
9 GHMM 3,776
10 IJF 2,046
Week's Top 5 Gainers
Symbol 8/12 8/19 % change
GNVC 2.33 2.78 19.31%
IDIX 4.16 4.84 16.35%
DNDN 10.37 12.06 16.30%
PGNX 5.75 6.44 12.00%
OMER 3.17 3.48 9.78%
Week's Top 5 Losers
Symbol 8/12 8/19 % change
GENT 8.90 6.65 -25.28%
AMRN 12.87 10.10 -21.52%
QCOR 31.56 26.70 -15.40%
TKMR 2.31 1.96 -15.15%
DVAX 2.40 2.07 -13.75% |
